

ASX/Media Release

### Lapse of Unlisted Options

**Immutep Limited** (ASX: IMM; NASDAQ: IMMP) advises that 79,311 unlisted options (ASX Code: IMMAL) over fully paid ordinary shares in the Company (exercise price of \$0.568, expiry on 30 October 2020) have lapsed in accordance with the terms of the options.

Total remaining securities under ASX Code: IMMAL are as follows:

- 102,628 options at an exercise price of \$0.398 expiring on 7 March 2021
- 847,600 options at an exercise price of \$0.248 expiring on 4 August 2025

#### About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 protein (LAG-3lg) based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada) referred to as TACTI-002 to evaluate a combination of efti with KEYTRUDA® (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinicaltrials.gov identifier NCT03252938); and a completed Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).

Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep's large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

This announcement was authorised for release by the Company Secretary of Immutep Limited.

Further information can be found on the Company's website [www.immutep.com](http://www.immutep.com) or by contacting:

#### Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS  
+61 (0)406 759 268; [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

#### U.S. Media:

Tim McCarthy, LifeSci Advisors  
+1 (212) 915.2564; [tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)